Sharif Ahmed, M.S, RAC, new Principal Consultant at Lachman Consultant Services, Inc.

We are pleased to announce that Sharif Ahmed has accepted the position of Principal Consultant in the Regulatory Practice at Lachman Consultants, effective February 20, 2017.

Mr. Ahmed has been functioning as a Senior Associate in the Regulatory Practice at Lachman Consultants since January 2016. He is a seasoned Regulatory professional with nearly 30 years of progressive responsibilities and is highly knowledgeable of the product approval processes of both the U.S.

happy

Cook Serves Up Numbers and Observations

Dr. Kathleen “Cook” Uhl, Director, Office of Generic Drugs told the story of the past, present, and future of GDUFA and how the industry and OGD are doing.  Interestingly, she noted this was the first meeting she had attended where she heard that industry members said they are happy!  Then she noted “you are not really happy,

aam

Association for Accessible Medicines –  What is This?

Today, at the Generic Pharmaceutical Association (GPhA) Annual Meeting, Chip Davis, the CEO of the “former” GPhA announced the rebranding of the association to its new name, the Association for Accessible Medicines (aam).  The change is designed to further the work of the industry group to provide more affordable medicines in both the generic and biosimilars space.

hiring

OMB Clarifies Hiring Freeze for FDA

A memo and its attachments was issued on February 6, 2017 to give various position classes, including pharmacist, consumer safety officers, microbiologists, chemists, medical officers, etc., which cover many of the FDA position classifications. Also, there is no freeze of the hiring of Commissioned Corps Officers of the United States Public Health Service.

Hopefully,

triple dollar sign - red stencil text on a paper price tag against rustic wood

States Getting into Pricing Issues – Look Out Below!

Seems like every day we see new proposed legislation being introduced into another state’s legislature.  Each one seems to have a somewhat different methodology or focus for controlling and reporting on drug prices.  Let’s think about this.  Everyone wants to strive for lower drug prices.  Remember, in the early 1980’s, the entire nation was focused on reducing health care costs and the Drug Price Competition and Patent Term Restoration Act of 1984 (better known as the Hatch-Waxman Act) came along to address drug prices and associated health care costs while providing additional protections for band name drug products. 

Frozen windows in winter time with frost decorations

Foreign Inspection Program Feels the Freeze

In the past week, the news media reported on President Trump’s meeting with some leaders of big pharma and among the themes discussed were the lowering of drug prices, cutting regulation, speeding up drug approvals and bringing jobs back to the U.S.  Previous postings have pointed out how the administration’s current freeze on Federal hiring may have the unintended effect of slowing drug approvals (see here).

Forearm showing Capillaritis or Leaking Capillaries

May Not Be a Rash Decision to Worry About a Rash

The FDA issued a safety warning on Thursday afternoon regarding the potential for rare but serious adverse reactions (including anaphylaxis, hives and severe rash) for a common skin sanitizing agent.  The warning focuses on chlorhexidine gluconate which is available both as a prescription and over-the-counter product for use as a skin sanitizer.  In addition, the product is also available in an oral for use in gum disease products but those products already have the warning.

accuracy level conceptual meter indicate hundred per cent, isolated on white background

Let’s See if We Get this Right

Remember the old FDA Monthly Approvals Report that never really provided numbers that matched the approvals that OGD reported in their Activities Report of the Generic Drug Program (Activities Report)?  (see story here). We reported a usual 5-10% discrepancy relative to approvals between the reports.  Well, the FDA Monthly Approval Report was discontinued many months ago,

FDA Badge

Who IS Going to Be the New Boss at FDA?

Well, not naming any names- I really won’t come out and say who my pick would be, but, depending on the administration’s pick, this is a pretty crucial decision for the Agency.  Here are some of the attributes I think would be important for the position:

  1. A knowledge of the FDA review and approval process
  2. A strong medical background
  3. A person that believes that science should rule the day
  4. Someone who is above the political fray
  5. A person that has both compassion and common sense
  6. Someone with an understanding of how the drug industry operated

Which of these attributes do I think is most important?